GLUE - Monte Rosa Therapeutics, Inc.
Shares of Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE - Get Free Report) have earned an average rating of "Moderate Buy" from the twelve brokerages that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, eight have given a buy
Monte Rosa Therapeutics (NASDAQ: GLUE - Get Free Report) and ImmunityBio (NASDAQ: IBRX - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation. Volatility and Risk Monte Rosa Therapeutics has a
Monte Rosa Therapeutics NASDAQ: GLUE reported results from GFORCE-1, a Phase I study of its NEK7-directed molecular glue degrader MRT-8102 in participants with elevated cardiovascular risk. The company said the four-week dosing study showed sustained degradation of NEK7, reductions in inflammatory and atherogenic biomarkers, and a safety profile comparable with placebo.
BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of inducement equity awards to five newly hired non-executive employees as a material inducement to commencing their employment with the Company. The employees received, in the aggregate, non-qualified stock options to purchase 86,725 shares of Monte Rosa Therapeutics common stock, par value $0.0001 per share, with an exercise price per share equal to the closing price of $11.26 as reported by Nasdaq on October 1, the effective date of the grant or the “Grant Date”, which will vest 25% on the first anniversary of the Grant Date and in 36 equal monthly installments thereafter, subject to the employee's continued service with the Company through each applicable vesting date; and restricted stock units for an aggregate of 19,150 shares of Monte Rosa Therapeutics common stock, which will vest 25% on each of the first four anniversaries of the Grant Date, subject to the employee's continued service with the Company through each applicable vesting date, or collectively, the Awards.
Monte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degrader MRT-8102 in Cardiovascular Disease Risk Transcript
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) reported Phase 1 trial results for its inflammatory disease drug candidate MRT-8102, while outlining plans to advance the treatment into multiple Phase 2 studies.
In obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1-driven inflammatory diseases, normalized multiple atherosclerotic cardiovascular disease (ASCVD) pathogenic drivers of local plaque inflammation, thrombosis, and systemic inflammation Robust and sustained NEK7 degradation observed across 5 mg, 20 mg, and 40 mg once-daily dose levels, with similar biomarker reductions at all three doses HMGB1, calprotectin, S100A12, and SAA, damage-associated molecular patterns (DAMPs) linked to atherosclerotic plaque progression and instability, and IL-1 β , all established key pathogenic drivers of ASCVD, were reduced to levels comparable to normal physiological levels seen in the healthy volunteer population of Phase 1 study MRT-8102 was safe and well tolerated over four weeks of dosing and four weeks of follow-up, with no serious adverse events, treatment-emergent adverse event rates comparable to placebo, and no evidence of increased infection risk Phase 2 trials planned across coronary artery disease (GFORCE-2), gout (GEMINI-1), and moderate to severe hidradenitis suppurativa (GALAXY-1) Company to host conference call and webcast today, Oct. 1, at 8:00 a.m. ET BOSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced positive data from GFORCE-1, a Phase 1 study evaluating MRT-8102, a NEK7-directed MGD being developed for the treatment of inflammatory conditions driven by the NEK7/NLRP3 pathway.
BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and webcast on Thursday, October 1, at 8:00 a.m.
Bank of America Corp DE purchased a new position in Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 254,561 shares of the company's stock, valued at approximately $6,160,000. Bank of
Shares of Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the nine research firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have assigned a
Monte Rosa Therapeutics (NASDAQ: GLUE - Get Free Report) and Cardiff Oncology (NASDAQ: CRDF - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends. Insider and Institutional Ownership 80.0% of
Phase 2 study to be conducted in participants with Sjögren's disease Novartis conducting study under global exclusive development and commercialization license agreement with Monte Rosa Monte Rosa to receive milestone payment based on first patient visit of Phase 2 clinical study Additional studies expected to evaluate the potential of MRT-6160 (DDY391) across immune-mediated diseases; Monte Rosa eligible for additional Phase 2 study initiation milestones BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that its collaborator Novartis has initiated a Phase 2 clinical study for the VAV1-directed MGD MRT-6160 (DDY391) in people living with Sjögren's disease (SjD), the second most prevalent rheumatic autoimmune disease1.
Monte Rosa Therapeutics is rated a risky Buy, with valuation hinging on the clinical success and milestone payments from its outlicensed flagship asset MRT-6160. MRT-6160, targeting autoimmune diseases, offers differentiated safety and oral convenience, with Phase 2 results as the key near-term catalyst for GLUE. GLUE maintains a robust $626 million cash position, providing a 3.5-year runway and cushioning downside risk amid high clinical trial expenses.
BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of inducement equity awards to six newly hired non-executive employees as a material inducement to commencing their employment with the Company.
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences: Wells Fargo 21st Annual Healthcare Conference (Boston, MA) – Markus Warmuth, M.D.
Bank of America Corp DE lifted its stake in Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) by 73.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 387,542 shares of the company's stock after buying an additional 163,971 shares during the period.
Monte Rosa FPD in MODeFIRe-1, a P2 Study of MRT-2359 in Combo w/ Apalutamide in Patients w/ AR Mutation-Positive Metastatic Castration-Resistant Cancer
Dimensional Fund Advisors LP boosted its holdings in shares of Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) by 83.2% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,041,372 shares of the company's stock after purchasing an additional 473,005 shares during the
Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to a loss of $0.15 per share a year ago.
Completed enrollment and dosing for GFORCE-1 study of MRT-8102 in subjects with elevated cardiovascular disease (CVD) risk; readout anticipated in H2 2026 Company expects to initiate multiple MRT-8102 Phase 2 studies, including in patients with elevated atherosclerotic risk and cardiometabolic syndrome in H2 2026, in patients with gout flares in Q4 2026/Q1 2027, and in patients with moderate to severe hidradenitis suppurativa in H1 2027 MODeFIRe-1 Phase 2 study of MRT-2359 activated, in combination with apalutamide in metastatic castration-resistant prostate cancer patients (mCRPC) with androgen receptor (AR) mutations Phase 2a/b clinical trial for VAV1-directed MGD MRT-6160 (DDY391) activated in participants with Sjögren's disease; study to be conducted by Novartis under global exclusive development and commercialization license agreement Strong balance sheet with cash, cash equivalents, restricted cash, and marketable securities of $626.0 million, expected to support operations into 2029 BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business highlights and financial results for the second quarter ended June 30, 2026. “We're tremendously proud of our progress to date in 2026, defined by strong execution across our clinical-stage portfolio, with two Phase 2 trials activated and additional trials expected across our programs,” said Markus Warmuth, M.D.